Pedram Argani, M.D.

Headshot of Pedram Argani
  • Associate Director, Surgical Pathology
  • Professor of Pathology


Kidney Cancer, Pathology

Research Interests

Breast cancer genetics; Breast cancer; Kidney cancer; Biliary cancer; Pediatric Neoplasms more


The Johns Hopkins Hospital (Main Entrance)

1800 Orleans St.
Sheikh Zayed Tower
Baltimore, MD 21287
Phone: 410-955-9790
The Johns Hopkins Hospital (Main Entrance) - Google Maps


Dr. Pedram Argani is a professor of pathology at the Johns Hopkins University School of Medicine. His area of clinical expertise is kidney cancer, particularly those arising in children. He is internationally recognized as an expert anatomic pathologist.

Dr. Argani serves as the associate director of Surgical Pathology and director of Surgical Pathology Fellowship.

He received his undergraduate degree from Princeton University. He earned his M.D. from University of Pennsylvania Health System School of Medicine where he also completed his residency in anatomic pathology. Dr. Argani performed a fellowship in oncologic and molecular pathology at Memorial Sloan-Kettering Cancer Center.

He is on the editorial board of numerous scientific journals, including the American Journal of Surgical Pathology, the American Journal of Clinical Pathology, Modern Pathology, and the International Journal of Surgical Pathology. Dr. Argani won the Arthur Purdy Stout Prize from the United States and Canadian Academy of Pathology for his contributions to the advancement of diagnostic pathology. more


  • Associate Director, Surgical Pathology
  • Director, Surgical Pathology Fellowship
  • Professor of Pathology
  • Professor of Oncology

Departments / Divisions

Centers & Institutes



  • MD; University of Pennsylvania Perelman School of Medicine (1992)


  • Anatomic Pathology; Hospital of the University of Pennsylvania (1995)


  • Oncologic Pathology; Memorial Sloan-Kettering Cancer Center (1996)
  • Memorial Sloan-Kettering Cancer Center (1997)

Board Certifications

  • American Board of Pathology (Anatomic Pathology) (1997)

Research & Publications

Selected Publications

  1. Fenton, H.; Carlile, B.; Montgomery, E.A.; Carraway, H.; Herman, J.; Sahin, F.; Su, G.H.; Argani, P. LKB1 protein expression in human breast cancer. Appl Immunohistochem Mol Morphol. 2006 Jun;14(2):146-153.
  2. Gallicchio, L.; Berndt, S.I.; McSorley, M.A.; Newschaffer, C.J.; Thuita, L.W.; Argani, P.; Hoffman, S.C.; Helzlsouer, K.J. Polymorphisms in estrogen-metabolizing and estrogen receptor genes and the risk of developing breast cancer among a cohort of women with benign breast disease. BMC Cancer. 2006;6:173.
  3. Gallicchio, L.; McSorley, M.A.; Newschaffer, C.J.; Thuita, L.W.; Argani, P.; Hoffman, S.C.; Helzlsouer, K.J. Flame-broiled food, NAT2 acetylator phenotype, and breast cancer risk among women with benign breast disease. Breast Cancer Res Treat. 2006 Sep;99(2):229-233.
  4. Hansel, D.E.; Meeker, A.K.; Hicks, J.; De Marzo, A.M.; Lillemoe, K.D.; Schulick, R.; Hruban, R.H.; Maitra, A.; Argani, P. Telomere length variation in biliary tract metaplasia, dysplasia, and carcinoma. Mod Pathol. 2006 Jun;19(6):772-779.
  5. Judson, K.; Argani, P. Intraductal spread by metastatic islet cell tumor (well-differentiated pancreatic endocrine neoplasm) involving the breast of a child, mimicking a primary mammary carcinoma. Am J Surg Pathol. 2006 Jul;30(7):912-918.
  6. Karakas, B.; Weeraratna, A.; Abukhdeir, A.; Blair, B.G.; Konishi, H.; Arena, S.; Becker, K.; Wood, W., 3rd; Argani, P.; De Marzo, A.M.; Bachman, K.E.; Park, B.H. Interleukin-1 alpha mediates the growth proliferative effects of transforming growth factor-beta in p21 null MCF-10A human mammary epithelial cells. Oncogene. 2006 Sep 7;25(40):5561-5569.
  7. Lo, P.K.; Mehrotra, J.; D''Costa, A.; Fackler, M.J.; Garrett-Mayer, E.; Argani, P.; Sukumar, S. Epigenetic suppression of secreted frizzled related protein 1 (SFRP1) expression in human breast cancer. Cancer Biol Ther. 2006 Mar;5(3):281-286.
  8. Swift-Scanlan, T.; Blackford, A.; Argani, P.; Sukumar, S.; Fackler, M.J. Two-color quantitative multiplex methylation-specific PCR. Biotechniques. 2006 Feb;40(2):210-219.
  9. Wu, X.; Chen, H.; Parker, B.; Rubin, E.; Zhu, T.; Lee, J.S.; Argani, P.; Sukumar, S. HOXB7, a Homeodomain Protein, Is Overexpressed in Breast Cancer and Confers Epithelial-Mesenchymal Transition. Cancer Res. 2006 Oct 1;66(19):9527-9534.
  10. Agoston, A.T.; Argani, P.; De Marzo, A.M.; Hicks, J.L.; Nelson, W.G. Retinoblastoma pathway dysregulation causes DNA methyltransferase 1 overexpression in cancer via MAD2-mediated inhibition of the anaphase-promoting complex. Am J Pathol. 2007 May;170(5):1585-1593.
  11. Argani, P.; Olgac, S.; Tickoo, S.K.; Goldfischer, M.; Moch, H.; Chan, D.Y.; Eble, J.N.; Bonsib, S.M.; Jimeno, M.; Lloreta, J.; Billis, A.; Hicks, J.; De Marzo, A.M.; Reuter, V.E.; Ladanyi, M. Xp11 translocation renal cell carcinoma in adults: expanded clinical, pathologic, and genetic spectrum. Am J Surg Pathol. 2007 Aug;31(8):1149-1160.
  12. Cornblatt, B.S.; Ye, L.; Dinkova-Kostova, A.T.; Erb, M.; Fahey, J.W.; Singh, N.K.; Chen, M.S.; Stierer, T.; Garrett-Mayer, E.; Argani, P.; Davidson, N.E.; Talalay, P.; Kensler, T.W.; Visvanathan, K. Preclinical and clinical evaluation of sulforaphane for chemoprevention in the breast. Carcinogenesis. 2007 Jul;28(7):1485-1490.
  13. Lee, J.S.; Lo, P.K.; Fackler, M.J.; Argani, P.; Zhang, Z.; Garrett-Mayer, E.; Sukumar, S. A Comparative Study of Korean with Caucasian Breast Cancer Reveals Frequency of Methylation in Multiple Genes Correlates with Breast Cancer in Young, ER, PR-negative Breast Cancer in Korean Women. Cancer Biol Ther. 2007 Apr 23;6:1114*1120.
  14. Shipitsin, M.; Campbell, L.L.; Argani, P.; Weremowicz, S.; Bloushtain-Qimron, N.; Yao, J.; Nikolskaya, T.; Serebryiskaya, T.; Beroukhim, R.; Hu, M.; Halushka, M.K.; Sukumar, S.; Parker, L.M.; Anderson, K.S.; Harris, L.N.; Garber, J.E.; Richardson, A.L.; Schnitt, S.J.; Nikolsky, Y.; Gelman, R.S.; Polyak, K. Molecular definition of breast tumor heterogeneity. Cancer Cell. 2007 Mar;11(3):259-273.
  15. Tsuda, M.; Davis, I.J.; Argani, P.; Shukla, N.; McGill, G.G.; Nagai, M.; Saito, T.; Lae, M.; Fisher, D.E.; Ladanyi, M. TFE3 fusions activate MET signaling by transcriptional up-regulation, defining another class of tumors as candidates for therapeutic MET inhibition. Cancer Res. 2007 Feb 1;67(3):919-929.
  16. Abukhdeir, A.M.; Vitolo, M.I.; Argani, P.; De Marzo, A.M.; Karakas, B.; Konishi, H.; Gustin, J.P.; Lauring, J.; Garay, J.P.; Pendleton, C.; Konishi, Y.; Blair, B.G.; Brenner, K.; Garrett-Mayer, E.; Carraway, H.; Bachman, K.E.; Park, B.H. Tamoxifen-stimulated growth of breast cancer due to p21 loss. Proc Natl Acad Sci U S A. 2008 Jan 8;105(1):288-293.
  17. Argani, P. Understanding Breast Pathology. The Johns Hopkins Breast Cancer Handbook of Healthcare Professionals. Sudbury: Jones and Bartlett Publishers; 2008. p. 37-58.
  18. Cao, D.; Polyak, K.; Halushka, M.K.; Nassar, H.; Kouprina, N.; Iacobuzio-Donahue, C.; Wu, X.; Sukumar, S.; Hicks, J.; De Marzo, A.; Argani, P. Serial analysis of gene expression of lobular carcinoma in situ identifies down regulation of claudin 4 and overexpression of matrix metalloproteinase 9. Breast Cancer Res. 2008;10(5):R91.
  19. Cao, D.; Tsangaris, T.N.; Kouprina, N.; Wu, L.S.; Balch, C.M.; Vang, R.; Argani, P. The superficial margin of the skin-sparing mastectomy for breast carcinoma: factors predicting involvement and efficacy of additional margin sampling. Ann Surg Oncol. 2008 May;15(5):1330-1340.
  20. Kleer, C.G.; Bloushtain-Qimron, N.; Chen, Y.H.; Carrasco, D.; Hu, M.; Yao, J.; Kraeft, S.K.; Collins, L.C.; Sabel, M.S.; Argani, P.; Gelman, R.; Schnitt, S.J.; Krop, I.E.; Polyak, K. Epithelial and stromal cathepsin K and CXCL14 expression in breast tumor progression. Clin Cancer Res. 2008 Sep 1;14(17):5357-5367.
  21. Lee, J.S.; Fackler, M.J.; Teo, W.W.; Lee, J.H.; Choi, C.; Park, M.H.; Yoon, J.H.; Zhang, Z.; Argani, P.; Sukumar, S. Quantitative promoter hypermethylation profiles of ductal carcinoma in situ in North American and Korean women: Potential applications for diagnosis. Cancer Biol Ther. 2008 Sep;7(9):1398-1406.
  22. Molavi, D.; Argani, P. Distinguishing benign dissecting mucin (stromal mucin pools) from invasive mucinous carcinoma. Adv Anat Pathol. 2008 Jan;15(1):1-17.
  23. Subhawong, A.P.; Subhawong, T.; Nassar, H.; Kouprina, N.; Begum, S.; Vang, R.; Westra, W.H.; Argani, P. Most Basal-like Breast Carcinomas Demonstrate the Same Rb-/p16+ Immunophenotype as the HPV-related Poorly Differentiated Squamous Cell Carcinomas Which They Resemble Morphologically. Am J Surg Pathol. 2008 Oct 17.
  24. Voltura, A.M.; Tsangaris, T.N.; Rosson, G.D.; Jacobs, L.K.; Flores, J.I.; Singh, N.K.; Argani, P.; Balch, C.M. Nipple-sparing mastectomy: critical assessment of 51 procedures and implications for selection criteria. Ann Surg Oncol. 2008 Dec;15(12):3396-3401.
  25. Wu, J.M.; Fackler, M.J.; Halushka, M.K.; Molavi, D.W.; Taylor, M.E.; Teo, W.W.; Griffin, C.; Fetting, J.; Davidson, N.E.; De Marzo, A.M.; Hicks, J.L.; Chitale, D.; Ladanyi, M.; Sukumar, S.; Argani, P. Heterogeneity of breast cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases. Clin Cancer Res. 2008 Apr 1;14(7):1938-1946.
  26. Albadine, R.; Wang, W.; Brownlee, N.A.; Toubaji, A.; Billis, A.; Argani, P.; Epstein, J.I.; Garvin, A.J.; Cousi, R.; Schaeffer, E.M.; Pavlovich, C.; Netto, G.J. Topoisomerase II alpha status in renal medullary carcinoma: immuno-expression and gene copy alterations of a potential target of therapy. J Urol. 2009 Aug;182(2):735-740.
  27. Argani, P.; Aulmann, S.; Karanjawala, Z.; Fraser, R.B.; Ladanyi, M.; Rodriguez, M.M. Melanotic Xp11 translocation renal cancers: a distinctive neoplasm with overlapping features of PEComa, carcinoma, and melanoma. Am J Surg Pathol. 2009 Apr;33(4):609-619.
  28. Axilbund, J.E.; Argani, P.; Kamiyama, M.; Palmisano, E.; Raben, M.; Borges, M.; Brune, K.A.; Goggins, M.; Hruban, R.H.; Klein, A.P. Absence of germline BRCA1 mutations in familial pancreatic cancer patients. Cancer Biol Ther. 2009 Jan;8(2):131-135.
  29. Carraway, H.E.; Wang, S.; Blackford, A.; Guo, M.; Powers, P.; Jeter, S.; Davidson, N.E.; Argani, P.; Terrell, K.; Herman, J.G.; Lange, J.R. Promoter hypermethylation in sentinel lymph nodes as a marker for breast cancer recurrence. Breast Cancer Res Treat. 2009 Apr 11;114:315-325.
  30. Chanjuan, S.; Argani, P. Synchronous primary perianal Paget''s disease and rectal adenocarcinoma: report of a hitherto undescribed phenomenon. Int J Surg Pathol. 2009 Feb;17(1):42-45.
  31. Cimino, A.; Halushka, M.; Illei, P.; Wu, X.; Sukumar, S.; Argani, P. Epithelial cell adhesion molecule (EpCAM) is overexpressed in breast cancer metastases. Breast Cancer Res Treat. 2009 Dec 11.
  32. Fackler, M.J.; Rivers, A.; Teo, W.W.; Mangat, A.; Taylor, E.; Zhang, Z.; Goodman, S.; Argani, P.; Nayar, R.; Susnik, B.; Sukumar, S.; Khan, S.A. Hypermethylated genes as biomarkers of cancer in women with pathologic nipple discharge. Clin Cancer Res. 2009 Jun 1;15(11):3802-3811.
  33. Higgins, J.P.; McKenney, J.K.; Brooks, J.D.; Argani, P.; Epstein, J.I. Recommendations for the reporting of surgically resected specimens of renal cell carcinoma: the Association of Directors of Anatomic and Surgical Pathology. Hum Pathol. 2009 Apr;40(4):456-463.
  34. Lo, P.K.; Watanabe, H.; Cheng, P.C.; Teo, W.W.; Liang, X.; Argani, P.; Lee, J.S.; Sukumar, S. MethySYBR, a novel quantitative PCR assay for the dual analysis of DNA methylation and CpG methylation density. J Mol Diagn. 2009 Sep;11(5):400-414.
  35. Martignoni, G.; Pea, M.; Gobbo, S.; Brunelli, M.; Bonetti, F.; Segala, D.; Pan, C.C.; Netto, G.; Doglioni, C.; Hes, O.; Argani, P.; Chilosi, M. Cathepsin-K immunoreactivity distinguishes MiTF/TFE family renal translocation carcinomas from other renal carcinomas. Mod Pathol. 2009 Aug;22(8):1016-1022.
  36. McDonald, O.G.; Rodriguez, R.; Bergner, A.; Argani, P. Metanephric Stromal Tumor Arising in a Patient With the Neurofibromatosis Type 1 Syndrome. Int J Surg Pathol. 2009 Oct 28.
  37. Ostrow, K.L.; Park, H.L.; Hoque, M.O.; Kim, M.S.; Liu, J.; Argani, P.; Westra, W.; Van Criekinge, W.; Sidransky, D. Pharmacologic unmasking of epigenetically silenced genes in breast cancer. Clin Cancer Res. 2009 Feb 15;15(4):1184-1191.
  38. Sausville, J.E.; Hernandez, D.J.; Argani, P.; Gearhart, J.P. Pediatric renal cell carcinoma. J Pediatr Urol. 2009 Aug;5(4):308-314.
  39. Shi, C.; Chandrasekaran, A.; Thuluvath, P.J.; Karikari, C.; Argani, P.; Goggins, M.; Maitra, A.; Eshleman, J.R. Ultrasensitive detection of KRAS2 mutations in bile and serum from patients with biliary tract carcinoma using LigAmp technology. J Mol Diagn. 2009 Nov;11(6):583-589.
  40. Subhawong, A.P.; Heaphy, C.M.; Argani, P.; Konishi, Y.; Kouprina, N.; Nassar, H.; Vang, R.; Meeker, A.K. The alternative lengthening of telomeres phenotype in breast carcinoma is associated with HER-2 overexpression. Mod Pathol. 2009 Nov;22(11):1423-1431.
  41. Subhawong, A.P.; Subhawong, T.; Nassar, H.; Kouprina, N.; Begum, S.; Vang, R.; Westra, W.H.; Argani, P. Most basal-like breast carcinomas demonstrate the same Rb-/p16+ immunophenotype as the HPV-related poorly differentiated squamous cell carcinomas which they resemble morphologically. Am J Surg Pathol. 2009 Feb;33(2):163-175.
  42. Cimino, A.; Halushka, M.; Illei, P.; Wu, X.; Sukumar, S.; Argani, P. Epithelial cell adhesion molecule (EpCAM) is overexpressed in breast cancer metastases. Breast Cancer Res Treat. 2010 Oct;123(3):701-708.
  43. Gupta, R.A.; Shah, N.; Wang, K.C.; Kim, J.; Horlings, H.M.; Wong, D.J.; Tsai, M.C.; Hung, T.; Argani, P.; Rinn, J.L.; Wang, Y.; Brzoska, P.; Kong, B.; Li, R.; West, R.B.; van de Vijver, M.J.; Sukumar, S.; Chang, H.Y. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature. 2010 Apr 15;464(7291):1071-1076.
  44. Jacobs, M.A.; Stearns, V.; Wolff, A.C.; Macura, K.; Argani, P.; Khouri, N.; Tsangaris, T.; Barker, P.B.; Davidson, N.E.; Bhujwalla, Z.M.; Bluemke, D.A.; Ouwerkerk, R. Multiparametric magnetic resonance imaging, spectroscopy and multinuclear ((2)(3)Na) imaging monitoring of preoperative chemotherapy for locally advanced breast cancer. Acad Radiol. 2010 Dec;17(12):1477-1485.
  45. Lewis, G.H.; Subhawong, A.P.; Nassar, H.; Vang, R.; Illei, P.; Park, B.H.; Argani, P. Relationships between Molecular Subtype of Invasive Breast Carcinoma (IBC) and Expression of Gross Cystic Disease Fluid Protein 15 (GCDFP) and Mammaglobin (MGB). American Journal of Clinical Pathology. 2010;In Press.
  46. Lo, P.K.; Lee, J.S.; Liang, X.; Han, L.; Mori, T.; Fackler, M.J.; Sadik, H.; Argani, P.; Pandita, T.K.; Sukumar, S. Epigenetic inactivation of the potential tumor suppressor gene FOXF1 in breast cancer. Cancer Res. 2010 Jul 15;70(14):6047-6058.
  47. Ohm, J.E.; Mali, P.; Van Neste, L.; Berman, D.M.; Liang, L.; Pandiyan, K.; Briggs, K.J.; Zhang, W.; Argani, P.; Simons, B.; Yu, W.; Matsui, W.; Van Criekinge, W.; Rassool, F.V.; Zambidis, E.; Schuebel, K.E.; Cope, L.; Yen, J.; Mohammad, H.P.; Cheng, L.; Baylin, S.B. Cancer-related epigenome changes associated with reprogramming to induced pluripotent stem cells. Cancer Res. 2010 Oct 1;70(19):7662-7673.
  48. Wu, J.M.; Halushka, M.K.; Argani, P. Intratumoral heterogeneity of HER-2 gene amplification and protein overexpression in breast cancer. Hum Pathol. 2010 Jun;41(6):914-917.
  49. Heaphy, C.M.; Subhawong, A.P.; Gross, A.L.; Konishi, Y.; Kouprina, N.; Argani, P.; Visvanathan, K.; Meeker, A.K. Shorter telomeres in luminal B, HER-2 and triple-negative breast cancer subtypes. Mod Pathol. 2011 Nov 5;24(2):194-200.

Argani P, Antonescu CR, Illei P, Timmons CF, Lui MY, Newbury R, Reuter VE,Garvin AJ, Perez-Atayde A, Fletcher JA, Beckwith JB, Bridge JA, and Ladanyi M. Primary Renal Neoplasms with the ASPL-TFE3 Gene Fusion of Alveolar Soft Part Sarcoma: A Distinctive Tumor Entity Previously Included among Renal Cell Carcinomas of Young People. Am J Pathol 2001; 159: 179-192.

Argani P, Rosty C, Reiter RE, Wilentz RE, Murugesan SR, Leach SR, Ryu B,Skinner HG, Goggins M, Jaffee EM, Yeo CJ, Cameron JL, Kern SE, and Hruban RH. Discovery of New Markers of Cancer Through Serial Analysis of GeneExpression (SAGE): Prostate Stem Cell Antigen (PSCA) is overexpressed in Pancreatic Adenocarcinoma. Cancer Research 2001;61: 4320-4324.

Argani P, Shaukat A, Kaushal M, Wilentz RE, Su GH, Sohn TA, Yeo CJ,Cameron JL, Kern SE, Hruban RH. Differing rates of loss of DPC4 expression and of p53 overexpression among carcinomas of the proximal and distal bile ducts: evidence for a biologic distinction. Cancer 2001;91: 1332-1341.

Argani P, Beckwith JB. Metanephric Stromal Tumor: Report of 31 cases of adistinctive pediatric renal neoplasm. Am J Surg Pathol 2000;24: 917-926.

Activities & Honors


  • Arthur Purdy Stout Prize, United States and Canadian Academy of Pathology, 2007
  • Professors’ Award for Excellence in Teaching, Johns Hopkins University School of Medicine, 2004

Professional Activities

  • Editorial board, American Journal of Surgical Pathology
  • Editorial board, American Journal of Clinical Pathology
  • Editorial board, Modern Pathology
  • Editorial board, International Journal of Surgical Pathology
  • Steering committee, Johns Hopkins University Medical School
  • Web master, Bile Duct and Gallbladder Cancer Web
Is this you? Edit Profile
back to top button